These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 37569851)

  • 1. Advances in the Management of Early-Stage Triple-Negative Breast Cancer.
    Bhardwaj PV; Wang Y; Brunk E; Spanheimer PM; Abdou YG
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?
    Gupta RK; Roy AM; Gupta A; Takabe K; Dhakal A; Opyrchal M; Kalinski P; Gandhi S
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The landscape of systemic therapy for early stage triple-negative breast cancer.
    Lu JY; Alvarez Soto A; Anampa JD
    Expert Opin Pharmacother; 2022 Aug; 23(11):1291-1303. PubMed ID: 35818711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer.
    Hao X; Gao X; Yin S; Jiang Z
    Transl Breast Cancer Res; 2023; 4():6. PubMed ID: 38751481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
    Bianchini G; De Angelis C; Licata L; Gianni L
    Nat Rev Clin Oncol; 2022 Feb; 19(2):91-113. PubMed ID: 34754128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer.
    Castellano G; Giugliano F; Curigliano G; Marra A
    Curr Opin Oncol; 2023 Nov; 35(6):479-490. PubMed ID: 37621170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    Landry I; Sumbly V; Vest M
    Cureus; 2022 Feb; 14(2):e21970. PubMed ID: 35282535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Sharma P
    Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
    Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC).
    Lee J
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer-A Review of Molecular Characterisation, Therapeutic Targets and Future Trends.
    Pinilla K; Drewett LM; Lucey R; Abraham JE
    Front Oncol; 2022; 12():866889. PubMed ID: 36003779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
    Desai NV; Tan AR
    JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response.
    De Santis P; Perrone M; Guarini C; Santoro AN; Laface C; Carrozzo D; Oliva GR; Fedele P
    Explor Target Antitumor Ther; 2024; 5(1):232-250. PubMed ID: 38464390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
    Dixon-Douglas J; Loi S
    Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of current progress in triple-negative breast cancer therapy.
    Shen M; Pan H; Chen Y; Xu YH; Yang W; Wu Z
    Open Med (Wars); 2020; 15(1):1143-1149. PubMed ID: 33336070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
    Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.
    Foldi J; Rozenblit M; Park TS; Knowlton CA; Golshan M; Moran M; Pusztai L
    Curr Treat Options Oncol; 2021 Jul; 22(9):79. PubMed ID: 34213636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.